{
    "relation": [
        [
            "",
            "Monotherapy",
            "Combination Therapy"
        ],
        [
            "Description",
            "2 tablets of darunavir (2 X 400 mg) and 1 tablet ritonavir (100 mg) administered once daily",
            "2 tablets of darunavir (2 X 400 mg) and 1 tablet ritonavir (100 mg) once daily + 2 nucleoside reverse transcriptase inhibitors (NRTIs)"
        ]
    ],
    "pageTitle": "A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT01391013?sect=X01256&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987135.9/warc/CC-MAIN-20150728002307-00151-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 856868739,
    "recordOffset": 856852801,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups 30 participants were randomly assigned to 2 treatment groups (15 participants in each group) and all participants received the study medication. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details 30 participants were enrolled at a single site in Italy. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Darunavir(DRV) Drug: Ritonavir Drug: 2 nucleoside reverse transcriptase inhibitors (NRTIs) Interventions: Human Immunodeficiency Virus 1 Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Monotherapy \u00a0 \u00a0 Combination Therapy \u00a0 STARTED \u00a0 \u00a0 15 \u00a0 \u00a0 15 \u00a0 COMPLETED \u00a0 \u00a0 15 \u00a0 \u00a0 15 \u00a0 NOT COMPLETED \u00a0 \u00a0 0 \u00a0 \u00a0 0 \u00a0 \u00a0 Baseline Characteristics \u00a0 Hide Baseline Characteristics Population Description Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. No text entered. Reporting",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}